Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease, today announced that it is pleased with the recent press coverage the Company and Dr. Daniel G. Chain, Ph.D., the Company's Chairman and Chief Executive Officer, recently has received.  A number of media outlets increasingly are focusing the attention of their audiences towards Alzheimer's disease, which has more than 5 million sufferers in the United States, and Dr. Chain's breakthrough efforts in finding a disease modifying treatment for this devastating, progressive, neurodegenerative and ultimately fatal disease.

On Monday, July 12, 2010, Dr. Chain was featured along with Dr. William Thies, Chief Medical & Scientific Officer of the Alzheimer's Association, on Southern California Public Radio, 89.3 KPCC by op-ed columnist and writer for the Los Angeles Times, Patt Morrison.  Dr. Chain was interviewed during the Alzheimer's Association International Conference (ICAD) taking place in Honolulu (July 10-15).  The conference is focused on the latest research on diagnosing, treating and preventing Alzheimer's disease.

Investors interested in hearing audio playback of the interview can find it at: http://www.scpr.org/programs/patt-morrison/2010/07/12/alzheimers-association-convenes-international-conf/

In addition, Dana Blakenhorn of ZDNet Healthcare, wrote about Dr. Chain in an article titled ,"An Alzheimer's cure could be closer than we think".  That article discusses Intellect's proprietary ANTISENILIN^® platform technology, which the Company has licensed to several major pharmaceutical companies that are developing drugs in Phase 1, Phase 2 and Phase 3 human clinical trials.  The article can be found at http://www.zdnet.com/blog/healthcare/an-alzheimers-cure-could-be-closer-than-we-think/3793

Those interviews and other opportunities to spread the word about Intellect Neurosciences' discoveries, research and development of proprietary drug candidates follow the Company's recent successful financial restructuring, which resulted in the extinguishment of approximately $24 million of aggregate face amount plus accrued interest of debt and preferred stock through the issuance of common stock.  Simultaneous with the restructuring, several of the Company's existing shareholders contributed additional funds and committed to support the Company's operations through completion of important future milestones.